Shopping Cart
- Remove All
- Your shopping cart is currently empty
TAS-114 is an orally active dual inhibitor of dUTPase and dihydropyrimidine dehydrogenase (DPD). TAS-114 targets the intercellular metabolism of 5-FU to enhance antitumor activity and modulates catabolic pathways to improve the systemic availability of 5-FU.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $299 | In Stock |
Description | TAS-114 is an orally active dual inhibitor of dUTPase and dihydropyrimidine dehydrogenase (DPD). TAS-114 targets the intercellular metabolism of 5-FU to enhance antitumor activity and modulates catabolic pathways to improve the systemic availability of 5-FU. |
In vitro | In HeLa, NUGC-4, NCI-H441, HT-29, CFPAC-1, and MCF-7 cell lines, TAS-114 (72 hours; 1 μM, 3 μM, and 10 μM) can significantly enhance the cytotoxicity of FdUrd and 5-FU against various cancer cell lines in a dose-dependent manner[1]. |
In vivo | In BALB/c nude mice with MX-1 human breast cancer xenografts, TAS-114 (37.5 to 1200 mg/kg/day; orally; daily; 1-14 days) can decrease the tolerable doses of Capecitabine (539 mg/kg/day) in a dose-dependent manner in mice[1]. |
Alias | TAS114, TAS 114 |
Molecular Weight | 451.54 |
Formula | C21H29N3O6S |
Cas No. | 1198221-21-4 |
Smiles | C[C@@H](NS(=O)(=O)CCCOCn1ccc(=O)[nH]c1=O)c1cccc(OC2CCCC2)c1 |
Relative Density. | 1.290 g/cm3 (Predicted) |
Storage | store at low temperature,store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 80 mg/mL (177.17 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.